Volume 6, Issue 12(Suppl)
Dentistry
ISSN: 2161-1122, an open access journal
Page 23
Notes:
American Dental Congress 2016
December 08-10, 2016
conferenceseries
.com
19
th
American Dental Congress
December 08-10, 2016 Phoenix, USA
Salivary IgA enhancement strategy for development of anti-caries mucosal vaccine
Huimin Yan
Wuhan Institute of Virology-Chinese Academy of Sciences, China
D
ental caries remains one of the most common global chronic diseases caused by
Streptococcus
mutans, which is prevalent all
over the world. A potent and effective anti-caries vaccine has long been expected for caries prevention but no vaccines have
been brought to market till now mainly due to the low ability to induce and maintain protective antibody in oral fluids. We explored
different fusion strategies for the generation of a single fusion protein composed of both caries vaccine antigen and flagellin. We
found that intranasal immunization with a single recombinant fusion protein of flagellin and PAc (KF-rPAc) can induce PAc-specific
salivary IgA antibody responses and endow protection against caries. Optimization of the fusion strategy by replacement of the
highly variable region of flagellin with caries vaccine antigen could increase specific IgA antibody response and protection efficacy.
Novel recombinant fusion proteins KFD2-rPAc in which the hyper-variable region of flagellin (KF) was replaced with PAc could
induce robust PAc-specific serum IgG and IgA as well as PAc-specific salivary IgA, meanwhile lower the antibody response against
KF compared with KF-rPAc. More importantly, KFD2-rPAc could provide higher protective efficacy than that by KF-rPAc, but
with limited anti-body response not needed for protection against caries. KFD2-rPAc can be a superior caries vaccine candidate for
possible clinical trial. In conclusion, the fusion protein composed of both caries vaccine antigen and flagellin is an effective strategy
to enhance salivary IgA response and anti-caries efficacy for development of caries mucosal vaccine.
Biography
Huimin Yan has completed his BS and PhD from Wuhan University, China. He has completed his Post-doctoral studies as a Research Associate in the Department of
Pathology, School of Medicine, Case Western Reserve University, USA on Mucosal Immunology. He is a Professor in Wuhan Institute of Virology, CAS and PI of Mucosal
Immunity Research Group.
hmyan@wh.iov.cnHuimin Yan, Dentistry 2016, 6:12(Suppl)
http://dx.doi.org/10.4172/2161-1122.C1.008